vs
PATHWARD FINANCIAL, INC.（CASH）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是Orthofix Medical Inc.的1.3倍（$276.3M vs $219.9M），PATHWARD FINANCIAL, INC.净利率更高（26.4% vs -1.0%，领先27.4%），过去两年PATHWARD FINANCIAL, INC.的营收复合增速更高（21.0% vs 8.0%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CASH vs OFIX — 直观对比
营收规模更大
CASH
是对方的1.3倍
$219.9M
净利率更高
CASH
高出27.4%
-1.0%
两年增速更快
CASH
近两年复合增速
8.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $219.9M |
| 净利润 | $72.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 26.4% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $3.35 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHOFIX
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $219.9M | ||
| Q3 25 | $186.7M | $205.6M | ||
| Q2 25 | $195.8M | $203.1M | ||
| Q1 25 | $274.8M | $193.6M | ||
| Q4 24 | $182.6M | $215.7M | ||
| Q3 24 | $179.5M | $196.6M | ||
| Q2 24 | $188.6M | $198.6M |
净利润CASHOFIX
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | $-2.2M | ||
| Q3 25 | $38.8M | $-22.8M | ||
| Q2 25 | $42.1M | $-14.1M | ||
| Q1 25 | $75.0M | $-53.1M | ||
| Q4 24 | $30.0M | $-29.1M | ||
| Q3 24 | $33.5M | $-27.4M | ||
| Q2 24 | $44.9M | $-33.4M |
毛利率CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | 0.2% | ||
| Q3 25 | 25.9% | -8.3% | ||
| Q2 25 | 24.1% | -7.9% | ||
| Q1 25 | 33.2% | -25.2% | ||
| Q4 24 | 19.8% | -5.3% | ||
| Q3 24 | 20.9% | -9.6% | ||
| Q2 24 | 27.1% | -12.5% |
净利率CASHOFIX
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | -1.0% | ||
| Q3 25 | 20.8% | -11.1% | ||
| Q2 25 | 21.5% | -6.9% | ||
| Q1 25 | 27.3% | -27.4% | ||
| Q4 24 | 16.4% | -13.5% | ||
| Q3 24 | 18.7% | -13.9% | ||
| Q2 24 | 23.8% | -16.8% |
每股收益（稀释后）CASHOFIX
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $-0.05 | ||
| Q3 25 | $1.69 | $-0.57 | ||
| Q2 25 | $1.81 | $-0.36 | ||
| Q1 25 | $3.14 | $-1.35 | ||
| Q4 24 | $1.23 | $-0.76 | ||
| Q3 24 | $1.34 | $-0.71 | ||
| Q2 24 | $1.78 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | $82.0M |
| 总债务越低越好 | $59.5M | — |
| 股东权益账面价值 | $850.7M | $450.0M |
| 总资产 | $7.1B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHOFIX
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | $82.0M | ||
| Q3 25 | $120.6M | $62.9M | ||
| Q2 25 | $258.3M | $65.6M | ||
| Q1 25 | $254.2M | $58.0M | ||
| Q4 24 | $597.4M | $83.2M | ||
| Q3 24 | $158.3M | $30.1M | ||
| Q2 24 | $298.9M | $26.4M |
总债务CASHOFIX
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | $157.2M | ||
| Q2 25 | $33.4M | $157.0M | ||
| Q1 25 | $33.4M | $156.9M | ||
| Q4 24 | $33.4M | $157.0M | ||
| Q3 24 | $33.4M | $118.5M | ||
| Q2 24 | $33.3M | $118.0M |
股东权益CASHOFIX
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $450.0M | ||
| Q3 25 | $858.0M | $442.5M | ||
| Q2 25 | $819.0M | $458.3M | ||
| Q1 25 | $814.7M | $458.3M | ||
| Q4 24 | $758.3M | $503.1M | ||
| Q3 24 | $822.5M | $525.9M | ||
| Q2 24 | $748.4M | $546.0M |
总资产CASHOFIX
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $850.6M | ||
| Q3 25 | $7.2B | $832.6M | ||
| Q2 25 | $7.2B | $837.2M | ||
| Q1 25 | $7.0B | $823.1M | ||
| Q4 24 | $7.6B | $893.3M | ||
| Q3 24 | $7.5B | $867.9M | ||
| Q2 24 | $7.5B | $882.0M |
负债/权益比CASHOFIX
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | 0.36× | ||
| Q2 25 | 0.04× | 0.34× | ||
| Q1 25 | 0.04× | 0.34× | ||
| Q4 24 | 0.04× | 0.31× | ||
| Q3 24 | 0.04× | 0.23× | ||
| Q2 24 | 0.04× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $27.7M | ||
| Q3 25 | $303.7M | $12.4M | ||
| Q2 25 | $30.4M | $11.6M | ||
| Q1 25 | $188.3M | $-18.4M | ||
| Q4 24 | $-71.7M | $23.7M | ||
| Q3 24 | $143.1M | $11.7M | ||
| Q2 24 | $113.2M | $9.0M |
自由现金流CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $16.8M | ||
| Q3 25 | $300.3M | $2.5M | ||
| Q2 25 | $27.7M | $4.5M | ||
| Q1 25 | $184.7M | $-25.1M | ||
| Q4 24 | $-73.8M | $15.2M | ||
| Q3 24 | $138.8M | $6.3M | ||
| Q2 24 | $111.0M | $-360.0K |
自由现金流率CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | 7.6% | ||
| Q3 25 | 160.9% | 1.2% | ||
| Q2 25 | 14.1% | 2.2% | ||
| Q1 25 | 67.2% | -13.0% | ||
| Q4 24 | -40.4% | 7.0% | ||
| Q3 24 | 77.3% | 3.2% | ||
| Q2 24 | 58.8% | -0.2% |
资本支出强度CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 4.9% | ||
| Q3 25 | 1.8% | 4.8% | ||
| Q2 25 | 1.4% | 3.5% | ||
| Q1 25 | 1.3% | 3.5% | ||
| Q4 24 | 1.1% | 4.0% | ||
| Q3 24 | 2.4% | 2.7% | ||
| Q2 24 | 1.2% | 4.7% |
现金转化率CASHOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
